Company: Autolus Therapeutics Limited
Symbol: AUTL
Description: They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.
Trade Date: 6/22
Shares: 7.81 million
Price Range: $15.00-$17.00
Underwriter(s): Goldman Sachs & Co., Jefferies
Co-Manager(s): Wells Fargo Securities, William Blair
Terms Added: 6-8-18
Business: They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using their broad suite of proprietary and modular T cell programming technologies, they are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. They believe their programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.
Insider Buying: Certain of their existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $60 million in shares of their common stock in this offering at the initial public offering price per share.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish